Thanks for continually reposting your free pearls of wisdom 😶
Intense interest & commitment are always impressive & notable! NWBO has sparked some interest… really makes ya think…
Thanks for highlighting “big pharma” again—it’s a fascinating topic…
The checkpoint inhibitor Opdivo (Nivolumab) made by Bristol Myers Squibb was slated to be studied at UCLA in combo with DCVax-L, but the contract negotiations did not work out and the study was withdrawn. But there is an ongoing study at UCLA with Merck’s checkpoint inhibitor Keytruda (pembrolizumab)…
✅️ Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO, and Dr. Kalinski recently cited MTA agreements with Merck.
Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.
Market Data 
Markets 
AI
